WTO TRIPS Council (June 2015): LDC Group Presentation on the Extension of the Decision for Pharmaceutical ProductsSubmitted by thiru on 10. June 2015 - 8:54
The LDC Group delivered the following statement on Wednesday, 8 June 2015 during WTO TRIPS Council discussions on their request on the extension of the decision on pharmaceutical products.
PRESENTATION BY THE LDCS GROUP TO THE TRIPS COUNCIL ON THE EXTENSION OF THE DECISION ON PHARMACEUTICAL PRODUCTS, 09-10 JUNE 2015
I make this presentation on behalf of the LDCs group. We thank you for calling this meeting and for your report.
WTO TRIPS Council: World Health Organization issues unequivocal support of LDC transition period for pharmaceutical productsSubmitted by thiru on 10. June 2015 - 5:15
Today, on Wednesday, 10 June 2015, the World Trade Organization's TRIPS Council discussed the LDC Group's Request for an Extension of the Transitional Period Under Article 66.1 of the TRIPS Agreement for Least Developed Country Members with Respect to Pharmaceutical Products and for Waivers from the Obligation of Articles 70.8 and 70.9 of the TRIPS Agreement (Source: IP/C/W/605).
WTO TRIPS Council (February 2015): EU statement on LDC extension of transition period for pharmaceutical productsSubmitted by thiru on 3. June 2015 - 4:25
The following statement was delivered by the European Union at the February 2015 session in response to the proposal by the LDC Group Request for an Extension of the Transitional Period Under Article 66.1 of the TRIPS Agreement for Least Developed Country Members with Respect to Pharmaceutical Products and for Waivers from the Obligation of Articles 70.8 and 70.9 of the TRIPS Agreement.
In particular, the European Union noted,
June 2015: WTO reports on India's Section 3(d) and compulsory licensing provisions - WTO Trade Policy Review - IndiaSubmitted by thiru on 2. June 2015 - 7:29
On 2 June 2015 and 4 June 2015, the World Trade Organization (WTO) is conducting a trade policy review of India. All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes place in the "Trade Policy Review Body which is actually the WTO General Council — comprising the WTO’s full membership — operating under special rules and procedures" (Source: WTO, Trade Policy Reviews: Brief Introduction).
WHA68: Statement of HAI/KEI on Follow-up to 2014 HLM on comprehensive review + assessment of prevention and control of NCDsSubmitted by thiru on 26. May 2015 - 2:22
On Tuesday, 26 May 2015, the following statement was delivered in Committee B of the 68th World Health Assembly on behalf of Stichting Health Action International and Knowledge Ecology International on the topic: Follow-up to the 2014 high-level meeting of the United Nations General Assembly to undertake a comprehensive review and assessment of the progress achieved in the prevention and control of noncommunicable diseases.
May 21, 2015- Agenda for KEI/KEI Europe panel on Compulsory licensing of patents on drugs, vaccines and diagnostic testsSubmitted by thiru on 20. May 2015 - 9:36
Compulsory licensing of patents on drugs, vaccines and diagnostic tests
Knowledge Ecology International (KEI) and Knowledge Ecology International Europe (KEI Europe):
DATE: Thursday, 21 May 2015
VENUE: Kofi Annan Room, UNAIDS, Avenue Appia 20
- Ellen 't Hoen, Medicines, Law and Policy
WHA68: Greek Minister of Health - Panagiotis Kouroumplis - calls for de-linkage of R&D from the price of health technologiesSubmitted by thiru on 18. May 2015 - 16:15
On Monday, 18 May 2015, the Greek Minister of Health, Panagiotis Kouroumplis, delivered the following speech at the World Health Assembly in Geneva, explicitly calling for the de-linkage of the "cost of R&D from the final price of medicines" while highlighting the deleterious effects of austerity measures eroding public health systems, counter to the theme of WHA68, "Resilient Health Systems".
Here is his speech in full:
Madam Director General, dear colleagues, excellencies, ladies and gentlemen
WHO Expert Committtee adds trastuzumab, imatinib, daclatasvir, sofosbuvir, bedaquiline and delaminid to EMLSubmitted by thiru on 8. May 2015 - 2:34
On Friday, 8 May 2015, the World Health Organization (WHO) unveiled its 19th WHO Model of Essential Medicines (April 2015).
With respect to cancer drugs (Section 8.2, Cytoxic and Adjuvant Medicines), the Executive Summary noted that the Committee added 16 new medicines.
WHO donors in 2014 (US, Gates Foundation, UK, GAVI and Canada): Setting the agenda for global public health?Submitted by thiru on 7. May 2015 - 4:46
In preparation for the 68th World Health Assembly, to be convened in Geneva from 18 May 2015 to 26 May 2015, the World Health Organization (WHO) prepared a document (A68/INF./1, 1 May 2015), entitled "Annex to the Financial Report for the year ended 31 December 2014, Voluntary contributions by fund and by contributor).
WIPO CDIP 15: Statement of Brazil on evaluation of the Project on Open Collaborative Projects and IP-Based ModelsSubmitted by thiru on 21. April 2015 - 4:00
On Tuesday, 21 April 2015, the 15th session of the World Intellectual Property Organization's (WIPO) Committee on Development and Intellectual Property (CDIP) considered the Evaluation Report for the Project on Open Collaborative Projects and IP-Based Models (CDIP/15/3). This project on open collaborate development models is based on Recommendation 36 of the WIPO which states,
Knowledge Ecology International (KEI) will present the following statement on 20 April 2015 to the Open Session of the 20th Expert Committee on the Selection and Use of Essential Medicines.
Statement of Knowledge Ecology International: WHO 20th Expert Committee on the Selection and Use of Essential Medicines, with specific focus on expanding access to new cancer drugs, when available at affordable prices
20 April 2015
Dear members of the WHO Expert Committee and the WHO secretariat,
TRIPS Council (October 2014): India calls for de-linkage and innovation inducement prizes at WTO discussions on IP & innovationSubmitted by thiru on 30. March 2015 - 3:25
In advance of the World Trade Organization's October 2014 session of the TRIPS Council, the European Union, Switzerland and the United States made a written request to the TRIPS Council to discuss "Intellectual Property and Innovation: Promoting Awareness; Case Studies" under agenda item 12. This marked the 7th time that the United States tabled an item to the TRIPS Council relating to intellectual property or innovation.
In the context of these October 2014 discussions of Intellectual Property and Innovation, the Government of India delivered the following intervention asserting that,
HRC28: Statement of the European Union- Cultural Rights (Response to SR Report on Copyright and Right to Science and Culture)Submitted by thiru on 12. March 2015 - 10:56
On Wednesday, 11 March 2015, Oliver Hall-Allen, First Counsellor, Delegation of the European Union to the United Nations Office in Geneva delivered the following statement in response to the presentation of the Special Rapporteur in the Field of Cultural Rights (Farida Shaheed) on her Report on Copyright policy and the right to science and culture (A/HRC/28/57).
Oliver Hall-Allen (blue tie, white shirt), First Counsellor, Delegation of the European Union to the United Nations Office in Geneva
HRC28: Statement of the United States of America - Cultural Rights (Response to SR Report on Copyright and Right to Culture)Submitted by thiru on 11. March 2015 - 18:19
On Wednesday, 11 March 2015, Ambassador Keith Harper, U.S. Representative to the Human Rights Council, delivered the following statement to the 28th Session of the Human Rights Council on the topic of cultural rights.
HRC28: Statement by Farida Shaheed, Special Rapporteur, on Copyright policy and the right to science and cultureSubmitted by thiru on 11. March 2015 - 5:45
On Wednesday, 11 March 2015, Farida Shaheed, the United Nations Special Rapporteur in the field of cultural rights presented her seminal report on Copyright policy and the right to science and culture (A/HRC/28/57) at the 28th session of the Human Rights Council in Geneva.
Highlights from the report's recommendations include the following: